Volgen
Elie Traer
Titel
Geciteerd door
Geciteerd door
Jaar
Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML
CD DiNardo, EM Stein, S de Botton, GJ Roboz, JK Altman, AS Mims, ...
New England Journal of Medicine 378 (25), 2386-2398, 2018
13382018
Functional genomic landscape of acute myeloid leukaemia
JW Tyner, CE Tognon, D Bottomly, B Wilmot, SE Kurtz, SL Savage, ...
Nature 562 (7728), 526-531, 2018
10302018
Elimination of Mcl-1 is required for the initiation of apoptosis following ultraviolet irradiation
D Nijhawan, M Fang, E Traer, Q Zhong, W Gao, F Du, X Wang
Genes & development 17 (12), 1475-1486, 2003
7502003
Proteogenomic and metabolomic characterization of human glioblastoma
LB Wang, A Karpova, MA Gritsenko, JE Kyle, S Cao, Y Li, D Rykunov, ...
Cancer cell 39 (4), 509-528. e20, 2021
3762021
Proteogenomic characterization of endometrial carcinoma
Y Dou, EA Kawaler, DC Zhou, MA Gritsenko, C Huang, L Blumenberg, ...
Cell 180 (4), 729-748. e26, 2020
3182020
Identification of interleukin-1 by functional screening as a key mediator of cellular expansion and disease progression in acute myeloid leukemia
A Carey, DK Edwards, CA Eide, L Newell, E Traer, BC Medeiros, ...
Cell reports 18 (13), 3204-3218, 2017
2182017
Proteogenomic insights into the biology and treatment of HPV-negative head and neck squamous cell carcinoma
C Huang, L Chen, SR Savage, RV Eguez, Y Dou, Y Li, ...
Cancer cell 39 (3), 361-379. e16, 2021
2092021
Cloning, expression, and chromosomal localization of human long-chain fatty acid-CoA ligase 4 (FACL4)
Y Cao, E Traer, GA Zimmerman, TM McIntyre, SM Prescott
Genomics 49 (2), 327-330, 1998
1441998
FGF2 from marrow microenvironment promotes resistance to FLT3 inhibitors in acute myeloid leukemia
E Traer, J Martinez, N Javidi-Sharifi, A Agarwal, J Dunlap, I English, ...
Cancer research 76 (22), 6471-6482, 2016
1362016
Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial
A Burd, RL Levine, AS Ruppert, AS Mims, U Borate, EM Stein, P Patel, ...
Nature medicine 26 (12), 1852-1858, 2020
1262020
Blockade of JAK2-mediated extrinsic survival signals restores sensitivity of CML cells to ABL inhibitors
E Traer, R MacKenzie, J Snead, A Agarwal, AM Eiring, T O'Hare, ...
Leukemia 26 (5), 1140-1143, 2012
1232012
Crosstalk between KIT and FGFR3 promotes gastrointestinal stromal tumor cell growth and drug resistance
N Javidi-Sharifi, E Traer, J Martinez, A Gupta, T Taguchi, J Dunlap, ...
Cancer research 75 (5), 880-891, 2015
1082015
Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid-and lymphoid-derived hematologic malignancies
SE Kurtz, CA Eide, A Kaempf, V Khanna, SL Savage, A Rofelty, I English, ...
Proceedings of the National Academy of Sciences 114 (36), E7554-E7563, 2017
1002017
The cloning and characterization of a novel human diacylglycerol kinase, DGKι
L Ding, E Traer, TM McIntyre, GA Zimmerman, SM Prescott
Journal of Biological Chemistry 273 (49), 32746-32752, 1998
991998
Integrative analysis of drug response and clinical outcome in acute myeloid leukemia
D Bottomly, N Long, AR Schultz, SE Kurtz, CE Tognon, K Johnson, M Abel, ...
Cancer cell 40 (8), 850-864. e9, 2022
962022
Alterations in acute myeloid leukaemia bone marrow stromal cell exosome content coincide with gains in tyrosine kinase inhibitor resistance
S Viola, E Traer, J Huan, NI Hornick, JW Tyner, A Agarwal, M Loriaux, ...
British journal of haematology 172 (6), 983, 2016
862016
Phase Ib study of the anti-TIM-3 antibody MBG453 in combination with decitabine in patients with high-risk myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML)
U Borate, J Esteve, K Porkka, S Knapper, N Vey, S Scholl, ...
Blood 134, 570, 2019
802019
Efficacy and safety of sabatolimab (MBG453) in combination with hypomethylating agents (HMAs) in patients (Pts) with very high/high-risk myelodysplastic syndrome (vHR/HR-MDS …
AM Brunner, J Esteve, K Porkka, S Knapper, E Traer, S Scholl, ...
Blood 138, 244, 2021
752021
Efficacy and safety of sabatolimab (MBG453) in combination with hypomethylating agents (HMAs) in patients with acute myeloid leukemia (AML) and high-risk myelodysplastic …
AM Brunner, J Esteve, K Porkka, S Knapper, N Vey, S Scholl, ...
Blood 136, 1-2, 2020
742020
Targeting BCL-2 and ABL/LYN in Philadelphia chromosome–positive acute lymphoblastic leukemia
JT Leonard, JSJ Rowley, CA Eide, E Traer, B Hayes-Lattin, M Loriaux, ...
Science translational medicine 8 (354), 354ra114-354ra114, 2016
702016
Het systeem kan de bewerking nu niet uitvoeren. Probeer het later opnieuw.
Artikelen 1–20